Almirall SA (ALM):企業の財務・戦略的SWOT分析

◆英語タイトル:Almirall SA (ALM) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH61113FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Almirall SA (ALM) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Almirall SA (Almirall) is a specialty pharmaceutical company that researches, develops, manufactures and commercializes proprietary medicines and licensed products. The company’s key area of focus is dermatology covering psoriasis, eczema, acne and other skin infections. It also develops products in the autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. The company also works together with small and medium sized companies for the development of drugs and their marketing. It operates through affiliates in Europe and Central America and has R&D centers in Spain and Germany. Almirall is headquartered in Barcelona, Spain.

Almirall SA Key Recent Developments

Feb 22,2021: Almirall’s 2020 full-year results
Feb 03,2021: Almirall announces Gianfranco Nazzi as new CEO
Nov 24,2020: Almirall announces collaborations with the University of South Australia and Santa Creu and Sant Pau Hospital Research Institute Foundation
Nov 24,2020: Almirall announces collaborations with the University of South Australia and Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau
Nov 11,2020: Pablo Alvarez appointed to President and GM of Almirall US

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Almirall SA – Key Facts
Almirall SA – Key Employees
Almirall SA – Key Employee Biographies
Almirall SA – Major Products and Services
Almirall SA – History
Almirall SA – Company Statement
Almirall SA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Almirall SA – Business Description
Geographical Segment: America, Asia and Africa
Performance
Geographical Segment: Corporate Management and Revenue not Allocated to Other Segments
Performance
Geographical Segment: EME
Performance
Geographical Segment: Spain
Performance
Almirall SA – Corporate Strategy
Almirall SA – SWOT Analysis
SWOT Analysis – Overview
Almirall SA – Strengths
Almirall SA – Weaknesses
Almirall SA – Opportunities
Almirall SA – Threats
Almirall SA – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Almirall SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Almirall SA, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 22, 2021: Almirall’s 2020 full-year results
Feb 03, 2021: Almirall announces Gianfranco Nazzi as new CEO
Nov 24, 2020: Almirall announces collaborations with the University of South Australia and Santa Creu and Sant Pau Hospital Research Institute Foundation
Nov 24, 2020: Almirall announces collaborations with the University of South Australia and Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau
Nov 11, 2020: Pablo Alvarez appointed to President and GM of Almirall US
Nov 09, 2020: Almirall demonstrates resilient performance year to date despite COVID-19 impacts
Nov 09, 2020: The Board of Directors nominates Carlos Gallardo as Vice President of the Board
Oct 16, 2020: Almirall launches its second innovation initiative for dermatology-focused digital health start-ups
Jul 27, 2020: Almirall: Sustained performance of key growth drivers and excellent progress on pipeline in H1 despite negative impact of COVID-19
Jul 22, 2020: Almirall calls for collaborative innovation to advance new treatments for skin diseases
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Almirall SA, Key Facts
Almirall SA, Key Employees
Almirall SA, Key Employee Biographies
Almirall SA, Major Products and Services
Almirall SA, History
Almirall SA, Subsidiaries
Almirall SA, Key Competitors
Almirall SA, Ratios based on current share price
Almirall SA, Annual Ratios
Almirall SA, Annual Ratios (Cont...1)
Almirall SA, Annual Ratios (Cont...2)
Almirall SA, Interim Ratios
Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Almirall SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Almirall SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Almirall SA (ALM):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SPI Energy Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Spi Energy Co Ltd (Spi Energy), formerly Solar Power Inc, is a photovoltaic (PV) solutions provider. The company offers development, financing, installation, operation and sale of utility-scale and residential solar power projects. It also operates online energy e-commerce and investment pla …
  • HIL Limited (HIL):企業の財務・戦略的SWOT分析
    HIL Limited (HIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Enanta Pharmaceuticals Inc (ENTA):企業の財務・戦略的SWOT分析
    Summary Enanta Pharmaceuticals Inc (Enanta) is a biotechnology company. It discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of n …
  • C3J Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary C3J Therapeutics Inc (C3J), formerly C3 Jian Inc, is a clinical-stage biotechnology company which concentrates on the development and commercialization of targeted and pathogen specific, antimicrobials that treat and prevent diseases caused by microbial dysbiosis. Its pipeline product portfo …
  • Samba Financial Group (1090):企業の財務・戦略的SWOT分析
    Samba Financial Group (1090) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Gold Fields Limited:企業の戦略・SWOT・財務情報
    Gold Fields Limited - Strategy, SWOT and Corporate Finance Report Summary Gold Fields Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Curetis NV (CURE):医療機器:M&Aディール及び事業提携情報
    Summary Curetis NV (Curetis) is a medical device company that offers molecular diagnosis solutions. The company provides diagnostic systems developed with Unyvero platform for severe infectious diseases. Its products are used in rapid diagnosis for cartridges, diseases such as implant and tissue inf …
  • Bright Horizons Family Solutions LLC (BFAM):企業の財務・戦略的SWOT分析
    Summary Bright Horizons Family Solutions LLC (Bright Horizons) is a provider of educational advisory services and child care services. The company offers curriculum and programs including early education and preschool, back-up child and adult care programs, infant care, toddler care, college coach, …
  • Fagron NV (FAGR):製薬・医療:M&Aディール及び事業提携情報
    Summary Fagron NV (Fagron), formerly Arseus NV is a pharmaceutical compounding solution provider. The company offers products such as raw materials, extracts and tinctures, flammable products, anesthesia, ointment bases, syrups, suspension media, triturations, phyto pharmaflore, medispend, capsicard …
  • Abg Sundal Collier Holding Asa
    Abg Sundal Collier Holding Asa - Strategy, SWOT and Corporate Finance Report Summary Abg Sundal Collier Holding Asa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Prologis, Inc.:企業の戦略・SWOT・財務情報
    Prologis, Inc. - Strategy, SWOT and Corporate Finance Report Summary Prologis, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Boralex Inc (BLX):企業の財務・戦略的SWOT分析
    Boralex Inc (BLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Verona Pharma Plc (VRP):製薬・医療:M&Aディール及び事業提携情報
    Summary Verona Pharma Plc (Verona Pharma) is a clinical-stage biotechnology company, which focuses on the research, discovery and development of first-in-class therapeutic drugs for the treatment of chronic respiratory and inflammatory diseases. The company's lead candidate, RPL554 is a bronchodilat …
  • Spritzer Bhd:企業の戦略・SWOT・財務分析
    Spritzer Bhd - Strategy, SWOT and Corporate Finance Report Summary Spritzer Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Achillion Pharmaceuticals Inc:企業の戦略的SWOT分析
    Achillion Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Recylex SA:企業の戦略・SWOT・財務情報
    Recylex SA - Strategy, SWOT and Corporate Finance Report Summary Recylex SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • XsunX Inc (XSNX):企業の財務・戦略的SWOT分析
    XsunX Inc (XSNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Catalyst Biosciences Inc:企業のM&A・事業提携・投資動向
    Catalyst Biosciences Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Catalyst Biosciences Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Planet Gas Ltd (PGS):石油・ガス:M&Aディール及び事業提携情報
    Summary Planet Gas Ltd (Planet Gas) is an upstream oil and gas company that offers acquisition, exploration, production and development of oil and gas properties in the US. The company holds interests in conventional and unconventional oil and gas projects in Australia. It projects explores for coal …
  • Range Resources Corp (RRC):石油・ガス:M&Aディール及び事業提携情報
    Summary Range Resources Corp (Range) is independent oil, natural gas and natural gas liquids (NGL) company that explores, develops, and acquires natural gas and oil properties in the US. It has oil and gas properties in the Appalachian basin and Northern Louisiana of the US. Range’s natural gas and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆